Does androgen deprivation therapy protect against severe complications from COVID-19?

TY - JOUR

T1 - Does androgen deprivation therapy protect against severe complications from COVID-19?

AU - Patel, V. G.

AU - Zhong, X.

AU - Liaw, B.

AU - Tremblay, D.

AU - Tsao, C. K.

AU - Galsky, M. D.

AU - Oh, W. K.

N1 - Funding Information: BL reported serving as a consultant for Amgen, AstraZeneca, and Baxter and receiving research funding from Bayer, Janssen, and Sanofi. CKT reported serving as a consultant for Pfizer, Clovis, Eisai, and Boehringer Ingelheim. MDG reported receiving research funding from AstraZeneca, Bristol-Myers Squibb, Dendreon, Genentech/Roche, Janssen Oncology, Merck, and Novartis; serving as a consultant for Aileron Therapeutics, Astellas Pharma, AstraZeneca, BioMotiv, Bristol-Myers Squibb, Dendreon, Dracen, Dragonfly Therapeutics, EMD Serono, Genentech, GlaxoSmithKline, Incyte, Inovio Pharmaceuticals, Janssen, Lilly, Merck, Novartis, NuMab, Pfizer, Seattle Genetics; owning stock of other ownership interests in Rappta therapeutics. WKO reported receiving research funding from Constellation Pharmaceuticals and Sotio; serving as a consultant for Amgen, AstraZeneca, Bayer, Checkpoint Sciences, Huya Biosciences, Janssen, Sanofi, Sema4, TeneoBio, and Tyme; owning stocks and other ownership interests in Bellicum Pharmaceuticals. All remaining authors have declared no conflicts of interest. Funding Information: None declared. BL reported serving as a consultant for Amgen, AstraZeneca, and Baxter and receiving research funding from Bayer, Janssen, and Sanofi. CKT reported serving as a consultant for Pfizer, Clovis, Eisai, and Boehringer Ingelheim. MDG reported receiving research funding from AstraZeneca, Bristol-Myers Squibb, Dendreon, Genentech/Roche, Janssen Oncology, Merck, and Novartis; serving as a consultant for Aileron Therapeutics, Astellas Pharma, AstraZeneca, BioMotiv, Bristol-Myers Squibb, Dendreon, Dracen, Dragonfly Therapeutics, EMD Serono, Genentech, GlaxoSmithKline, Incyte, Inovio Pharmaceuticals, Janssen, Lilly, Merck, Novartis, NuMab, Pfizer, Seattle Genetics; owning stock of other ownership interests in Rappta therapeutics. WKO reported receiving research funding from Constellation Pharmaceuticals and Sotio; serving as a consultant for Amgen, AstraZeneca, Bayer, Checkpoint Sciences, Huya Biosciences, Janssen, Sanofi, Sema4, TeneoBio, and Tyme; owning stocks and other ownership interests in Bellicum Pharmaceuticals. All remaining authors have declared no conflicts of interest.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85089973689&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.06.023

DO - 10.1016/j.annonc.2020.06.023

M3 - Letter

C2 - 32653425

AN - SCOPUS:85089973689

SN - 0923-7534

VL - 31

SP - 1419

EP - 1420

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -